Summary The influence of tamoxifen on plasma lipids and lipoproteins was monitored in 46 postmenopausal and 8 premenopausal women treated for advanced breast cancer up till 6 months. Total cholesterol (total-C) did not significantly change. However, high density lipoprotein cholesterol (HDL-C) and the HDL-C/ total-C ratio rose significantly. Low density lipoprotein cholesterol was significantly decreased. Triglycerides and free fatty acids did not change markedly. The concomitant rise of sex hormone binding globulin and thyroxine binding globulin indicates that the increase of HDL-C with prolonged use of tamoxifen is compatible with an intrinsic oestrogenic effect of tamoxifen on the liver. The increased HDL-C/total-C ratio lends no support to the concern that long-term administration of this anti-oestrogenic drug might lead to an increased cardiovascular risk.
Treatment with tamoxifen is now widely accepted as the first-line endocrine treatment of choice in advanced breast cancer. Objective tumour responses are seen in some 30% of all cases in pre-and postmenopausal patients. The mean duration of tumour remission is 11 to 12 months, but responses lasting a few years are no exception (Mouridsen et al., 1978) .
In some countries tamoxifen is also prescribed for benign breast conditions, generally to premenopausal women and often for periods longer than one year. The use of tamoxifen as an adjuvant after curative treatment for primary breast cancer is currently widely employed. As reported recently (Anonymous, 1987) , at least forty-two randomised trials assessing adjuvant tamoxifen have been identified. Most trials concern postmenopausal patients having axillary node metastasis, but results from the Scottish trial showed a highly significant delay in relapse in the tamoxifen treated patients compared to the control arm patients, irrespective of menopausal or nodal status (Anonymous, 1987) . The optimal duration of adjuvant tamoxifen treatment is not yet known, but may be at least 5 years or even life-long. The success of adjuvant therapy has already elicited proposals for prevention trials in women carrying a high risk of developing breast cancer (Cuzick et al., 1986) . Tamoxifen has very few clinical side-effects of which hardly any is serious enough to urge its withdrawal. However, very little is known about possible long-term toxicity. One undesired long-term effect might be a reduction of the protection from cardiovascular disease, which women owe to their sex, most likely due to oestrogenic hormones (Gordon et al., 1978; Rosenberg et al., 1981; Wilson et al., 1987) .
There is no doubt that the serum level of total cholesterol (total-C) which is mainly determined by low density lipoprotein cholesterol (LDL-C), ranks, along with cigarette smoking and hypertension, as one of the three major risk factors for coronary heart disease (Levy, 1983) . The serum level of high density lipoprotein cholesterol (HDL-C) on the other hand is an independent factor which is inversely correlated with cardiovascular risk (Levy, 1981) . A recent position statement by the American Heart Association underlined the importance of total-C and HDL-C as cardiovascular risk factors (Grundy et al., 1987) .
A 20-year old follow-up study of coronary artery disease in Israel has demonstrated that the HDL-C/total-C ratio is a significant risk factor in men and women, both at high and low levels of total-C (ranging from more than 6.8 mM to less than 5.2mM) (Brunner et al., 1987) . Serum lipoproteins are influenced by sex hormones, estrogens causing an increase of HDL (Krauss, 1982) . It could be anticipated that the longterm use of an anti-oestrogenic drug like tamoxifen might entail a decrease of the HDL-C/total C ratio, and thereby contribute to the risk of cardiovascular disease. We have recently reported that prolonged administration to patients with advanced breast cancer responsive to tamoxifen has not caused any deterioration of the HDL-C/total C-ratio. On the contrary, apparently due to its intrinsic oestrogenic activity, tamoxifen resulted in an increase of HDL-C and a decrease of LDL-C (Bruning et al., 1987) .
Patients and methods
Eight premenopausal (mean age 43.3 + 3.6 yrs) and 46 postmenopausal women (mean age 63.2 + 9.5 yrs) with advanced breast cancer were treated with tamoxifen 10 mg t.i.d. Blood samples were collected after a 12 h fast, in dry lithiumheparinized Vacutainer't glass tubes, early in the morning, before treatment (to) and after 2 months of therapy (t2). In the patients who responded to therapy (4 premenopausal and 31 postmenopausal) samples were also collected after 6 months (t6).
All patients were requested to fill in a questionnaire on their smoking and drinking habits, and the concomitant use of drugs, which could affect lipoprotein values. Patients with diabetes mellitus or thyroid function abnormalities were not eligible for the study.
Cholesterol and triglycerides (TG) were measured enzymatically with a test kit from Boehringer Diagnostica (Mannheim, W. Germany). HDL-C was measured in the supernatant after precipitation of all other lipoproteins with phosphotungistic acid and magnesiumchloride (Burstein et al., 1970; Lopes-Virella, 1977) . LDL-C was calculated according to Friedewald et al. (1972) . Free fatty acids (FFA) were measured colorimetrically (Regouw et al., 1971) . The assays of oestrone, oestradiol, testosterone, thyrotropin (TSH) and free thyroxine index have been described elsewhere (Bruning et al., 1984) .
Sex hormone binding globulin (SHBG) was measured with an IRMA-kit from Farmos Diagnostica (Oulunsalo, Finland) . Changes in time and differences between pre-and postmenopausal women were tested by two-way analysis of variance. Based on normal probability plots, which were made first for all data, the basic analysis was performed on log-values.
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In Tables I and II the results are shown for pre-and postmenopausal patients, respectively, The mean log values at to and t2, or to and t6, as well as the mean values obtained by transformation from log to normal are presented. Total-C showed a trend to decrease, especially in the premenopausal women. HDL-C did not change before 2 months, but was significantly increased after 6 months of treatment both in pre-and postmenopausal patients. As a result, the HDL-C/total-C ratio increased significantly after 6 months, irrespective of menopausal status. Interestingly, at 2 months there was a significant difference for HDL-C and the HDL-C/total-C ratio in patients responding to tamoxifen compared to non-responders. The latter showed a decreasing HDL-C and a stable HDL-C/total-C ratio, whereas responding patients had stable HDL-C and increasing HDL-C/total-C values. This difference for HDL-C (P=0.01) and HDL-C/ total-C ratio (P <0.05) was observed in both pre-and postmenopausal women.
LDL-C significantly decreased already after 2 months, both before and after menopause. TG and FFA did not significantly change after 6 months. Only FFA levels rose temporarily at 2 months (P <0.05) in both menopausal groups. The premenopausal patients were bled at different time points of their menstrual cycles which may have an influence on the observed figures. Certainly, the number of observed premenopausal steroid levels was too small for any conclusion. Tamoxifen had no significant effect on the plasma concentrations of postmenopausal oestrogens or testosterone. However, SHBG was markedly increased after 2 and 6 months, pre-and postmenopausally.
Thyroid function remained stable, as indicated by the free thyroxine index and clinical picture. However, at the same time thyroxine levels rose significantly with a concomitant drop of triiodothyroxine resin uptake (P<0.0001) and a slight, but significant rise of TSH (P<0.05). These effects, which are indicative of an increased level of thyroxine binding globulin were already apparent at 2 months, and persisted through 6 months in pre-and postmenopausal patients alike.
Only related to an increase of cardiovascular risk (Wilson et al., 1987; Gordon et al., 1978; Rosenberg et al., 1981) . Other studies have indicated that oral oestrogen replacement treatment may reduce risk (Bain et al., 1981; Ross et al., 1981) . Unfortunately, as yet no prospective data on the long-term use of tamoxifen and cardiovascular risk have been published, or are likely to be available in the nearest future. It is therefore reassuring that the results from the present study do not show an adverse effect of prolonged anti-oestrogenic treatment with tamoxifen on one of the three major risk factors for coronary disease. Instead LDL-C is reduced and HDL-C with its cholesterol scavenging properties, and the HDL-C/total-C ratio appear to be significantly increased by prolonged use of tamoxifen. This favourable result is compatible with the known fact that tamoxifen can exert some oestrogenic activity (Patterson et al., 1982) .
The increase of the high density lipoprotein cholesterol,sex hormone binding globulin and, as demonstrated indirectly in this study, of thyroxine binding globulin in plasma suggests that tamoxifen stimulates liver protein synthesis, just like 17fl-oestradiol does, when given orally (Fahraeus et al., 1982; Fex et al., 1981) . Although our findings could also be explained by decreased protein degradation, proteinspecific stimulation of production seems more likely. Our data confirm and expand earlier data (Rossner & Wallgren, 1984) , which showed that short term tamoxifen treatment during 2 months, resulted in a decrease of LDL-C, haptoglobin and orosomucoid, but an increase of a-antitrypsin and ceruloplasmin. These findings and our own data are compatible with a mild oestrogen-like effect.
Our observations could not be explained by changes in body-weight, smoking, drinking habits, or the use of concomitant drugs, such as beta-blockers, tranquillizers or barbiturates. Only 3 patients used beta-blockers and 14 women were using minor tranquillizers (mainly oxazepam) throughout the observation period.
It is not clear why patients, who do not respond to tamoxifen and who stop taking the drug after 2 to 3 months, significantly differ from responding patients with regard to HDL-C and HDL-C/total-C ratio as early as after 2 months of tamoxifen. No such difference was observed for sex hormone binding globulin or thyroxine binding globulin. It seems therefore unlikely, that the lower HDL-C in the nonresponders can be explained by a lack of liver response to tamoxifen, or by a less good patient compliance, leading to inadequate tamoxifen intake and less tumour response. Increased degradation of HDL-C may be an early sign of failing therapy, which deserves further investigation.
The main conclusion from this study is that prolonged use of tamoxifen is not likely to contribute to cardiovascular risk by way of known serum lipoprotein risk factors.
